{
    "clinical_study": {
        "@rank": "79106", 
        "arm_group": {
            "arm_group_label": "DCVAC/PCa Arm", 
            "arm_group_type": "Experimental", 
            "description": "DCVAC/PCA Experimental therapy"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety of the second cycle of DCVAC/PCa in\n      patients who completed the first cycle of DCVAC/PCa in the clinical trial SP003 without an\n      objective progression of the disease."
        }, 
        "brief_title": "Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male 18 years and older\n\n          -  Histologically confirmed prostate adenocarcinoma Stage pT2\n\n          -  Post radical Primary Prostatectomy\n\n          -  Completion of DCVAC/PCa arm in Study SP003, without objective progression of the\n             disease\n\n        Exclusion Criteria:\n\n          -  Prior androgen deprivation therapy for prostate cancer\n\n          -  Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater\n\n          -  Other uncontrolled intercurrent illness\n\n          -  Treatment with immunotherapy against PCa\n\n          -  Clinically significant cardiovascular disease\n\n          -  Active autoimmune disease requiring treatment"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137746", 
            "org_study_id": "SP010", 
            "secondary_id": "2013-003809-26"
        }, 
        "intervention": {
            "arm_group_label": "DCVAC/PCa Arm", 
            "description": "DCVAC/PCa Experimental therapy", 
            "intervention_name": "DCVAC/PCa", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prostate Cancer", 
            "Radical Prostatectomy", 
            "Localized prostate cancer after primary radical prostatectomy"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Jablonec nad Nisou", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novy Jicin", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olomouc", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Usti nad Labem", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open-label, One-arm, Multi-centre Phase II Clinical Trial Treated With Second Cycle of Active Cellular Immunotherapy With DCVAC/PCa in Patients With Localized Prostate Cancer After Primary Radical Prostatectomy and Without Objective Progression on the First Cycle of DCVAC/PCa", 
        "overall_contact": {
            "email": "kapsa@sotio.com", 
            "last_name": "Richard Kapsa", 
            "phone": "(+420) 2241 74448"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Czech Republic: State Institute for Drug Control", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety evaluation of the second cycle of active cellular immunotherapy, which includes a second leukapheresis procedure, who after primary radical prostatectomy completed first cycle of active cellular immunotherapy in clinical trial SP003 without objective disease progression requiring additional anti-tumor therapy.", 
            "measure": "Safety evaluation of the second cycle of DCVAC", 
            "safety_issue": "Yes", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137746"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Time to Prostate Specific Antigen (PSA) Doubling Time", 
            "safety_issue": "Yes", 
            "time_frame": "52 weeks"
        }, 
        "source": "Sotio a.s.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sotio a.s.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}